4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) operates in the Biotechnology industry and is headquartered in Wuhan, China with about 60 employees. Its market capitalization is roughly HK$4 billion. In the fiscal year ended 2025-12-31, 3378 reported CNY 0M in revenue and (CNY 131M) in net income.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies.
Interactive charts & full statements → Open the 3378 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 150M) | (CNY 119M) | (CNY 61M) |
| Net Income | (CNY 131M) | (CNY 116M) | (CNY 76M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | CNY 936M | CNY 502M | CNY 586M |
| Total Liabilities | CNY 188M | CNY 285M | CNY 267M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3378 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms